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Abstract
Background: Although transforming growth factor β (TGF-β) typically inhibits proliferation of
epithelial cells, consistent with a tumor suppressor activity, it paradoxically also exhibits pro-
metastatic activity in the later stages of carcinogenesis. Since tumors often display altered TGF-β
signaling, particularly involving the Smad-pathway, we investigated the role of Smad4-expression in
breast cancer.
Methods: Smad4 expression was investigated by immunohistochemistry in formalin-fixed, paraffin-
embedded tissue from 197 samples of primary breast cancer obtained between 1986 and 1998. The
prognostic value of Smad4-expression was analyzed.
Results: Smad4 expression was found to be reduced in lobular and ductal breast carcinoma as
compared to surrounding uninvolved lobular and ductal breast epithelia (p < 0.001, n = 50). Smad4-
expression correlated positively with expression of TGF-β-receptor I (p < 0.001, n = 197) and
TGF-β-receptor II (p < 0.001, n = 197), but showed no significant correlation with tumor size,
metastases, nodal status, histological grade, histological type, or estrogen receptor expression.
While not achieving statistical significance, there was a trend towards longer survival times in
patients with Smad4 negative tumors.
Conclusion: According to the suggested role of Smad4 as a tumor suppressor we observed that
expression of Smad4 is lower in human breast cancer than in surrounding breast epithelium.
However, we also observed a trend towards longer survival times in Smad4-negative patients,
indicating the complex role of TGF-β signaling in tumor progression.
Background
Transforming growth factor beta (TGF-β) is an important
regulator of epithelial cell growth. Conflicting data exist
about the influence of TGF-β on the development and
progression of breast cancer. The growth of many human
breast cancer cell lines is inhibited by TGF-β [1,2] due to
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an inhibition of cell division and an induction of apopto-
sis. This is consistent with a tumor suppressor effect in
well-differentiated tumors [3,4]. On the other hand, cer-
tain highly aggressive breast cancer cell lines are refractory
to suppressive effects of TGF-β on cell growth and may
acquire sensitivity to pro-metastatic effects of TGF-β in
later stages of tumorigenesis [5-8].
Smad proteins are the principal transducers of signals
from TGF-β. TGF-β binds to homodimers of the TGF-β
type II receptor (TβRII) which recruits and activates
homodimers of TGF-β type I receptor (TβRI) serine/threo-
nine kinase. Activated TβRI phosphorylates Smad2 or
Smad3 [9,10] which heterodimerize with Smad4. These
heterocomplexes translocate into the nucleus where they
bind DNA and regulate TGF-β dependent gene expression
[11]. TGF-β signaling is altered in various tumors. We
have recently shown that loss of TβRII expression corre-
lated significantly with better prognosis in estrogen recep-
tor negative breast cancer patients [12], but little is known
about the influence of the various downstream TGF-β sig-
nal transduction pathways on breast cancer prognosis.
Deletions or mutations of Smad4 (also known as DPC4,
deleted in pancreatic cancer), a tumor suppressor [13] and
the only known co-Smad protein in TGF-β-, activin- and
bone morphogenetic protein-signaling, are found in vari-
ous epithelial tumors, including pancreatic carcinoma
[14,15], esophageal carcinoma [16], colorectal carcinoma
[17], renal cell carcinoma [18], as well as breast carcinoma
[19,20]. However, little is known about the expression
level of Smad4 or its prognostic significance in breast can-
cer.
In order to gain further insight into the status of Smad sig-
nal transduction in breast cancer progression, we used
immunohistochemistry to analyze the expression of
Smad4 in archival tissues of 197 breast cancer patients.
Smad4 expression in tumor tissues was compared to that
of surrounding normal tissues and correlated to estab-
lished prognostic markers for breast cancer as well as over-
all survival.
Methods
Specimens
Formalin-fixed, paraffin-embedded invasive breast carci-
nomas collected from 1987 to 1998 were retrieved from
the archives of pathology of the Robert Bosch Hospital
Stuttgart. Clinical and pathological data were retrieved
from clinical databases as well as from the archives of
pathology and included estrogen receptor, progesterone
receptor, TGF-β-receptor I, TGF-β-receptor II, tumor size,
nodal metastases, metastases, histological grade, tumor
stage, histological type, age, menopausal status, therapy,
and survival time of patients. Cases with incomplete clin-
ical data sets or without sufficient archived tissues were
excluded from the study (number of included cases: 197,
number of excluded cases: 69, drop out rate: 25.9 %).
Cell cultures
MCF-7 and MDA468 cells were grown in Dulbecco's mod-
ified Eagles medium (DMEM, Invitrogen, Carlsbad, USA)
supplemented with 10% fetal calf serum (Invitrogen).
Culture of MCF10CA1a, MCF10CA1h, MCF10A1k.cl2,
and MCF10A cells is described elsewhere [21].
Detection of Smad4
3  µm paraffin sections were dewaxed by routine tech-
niques. Immunohistochemistry was performed by the
EnVision-technique (DAKO, Hamburg, Germany) using
an Autostainer (DAKO). In brief, slides were soaked with
antigen retrieval buffer (DAKO) and microwave-treated (3
× 5 min, 600 W) followed by treatment with blocking
solution (methanol/H2O2) to block endogenous peroxi-
dase. Slides were incubated at room temperature for 30
min with a monoclonal antibody to Smad4 (clone B-8,
Santa Cruz Biotechnology Inc, Heidelberg, Germany)
diluted 1:50 with antibody dilution medium (DAKO),
and for 30 min with peroxidase-labeled polymer (DAKO).
Anti-Smad4-antibody was detected by 3,3'-diaminobenzi-
dine/ H2O2 containing staining solution. Sections were
counterstained with hematoxylin. Negative controls were
set up by omitting the primary antibody or the peroxidase
labeled polymer. As a positive control specimens were
stained with a different primary antibody to Smad4 (clone
DCS-46, acris, Bad Nauheim, Germany) which yielded
results identical to clone B-8 (data not shown). Immunos-
taining using an antibody to cytokeratin 18 (DAKO) was
used as an additional control for the staining method.
To obtain specimens for immunocytochemistry, cells
were grown on sterile coverslips to 70% to 80% conflu-
ence and fixed in acetone (-20°C, 5 min). For detection of
Smad4 the protocol described above was slightly modi-
fied: No antigen retrieval was performed and specimens
were incubated with the primary antibody (anti-Smad4,
1:50 in TBST) at room temperature overnight.
Immunohistological labeling was evaluated for tumor tis-
sues as well as for adjacent, unaffected breast epithelia
(i.e. breast epithelia not containing DCIS, LCIS or atypical
ductal hyperplasia) by scoring staining intensity as: 0
(negative), 1 (weak), 2 (moderate), 3 (strong) as well as
by scoring the fraction of Smad4-positive tumors cells: 1
(0% to 20%), 2 (21% to 50%), 3 (51% to 80%), 4 (81%
to 100%). An Immunoreactive Score (IRS) was calculated
by multiplying "staining intensity score" by "fraction of
positive cells"[22]. IRS = 0 was defined as Smad4 – nega-
tive, an IRS between 1 and 12 (1≤IRS≤12) as Smad4-pos-
itive. Specimens were scored by 2 investigators and in
cases of conflict, specimens were re-evaluated together.BMC Cancer 2006, 6:25 http://www.biomedcentral.com/1471-2407/6/25
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Detection of TGF-β receptors
Immunostaining of TβRI and TβRII was described earlier
[12].
Immunoblotting
For Western blots cells were grown to 80% – 90% subcon-
fluent monolayers and processed as described elsewhere
[23] using a monoclonal antibody against Smad4 (clone
B-8, Santa Cruz Biotechnology Inc, Santa Cruz, California,
USA), or a monoclonal antibody against α-tubulin
(Zymed Laboratories Inc, San Francisco, California, USA).
For dot blots tumor tissues were snap frozen, homoge-
nized by use of a Mikro Dissmembrator S (Braun Biotech
International, Melsungen Germany), and incubated with
lysis buffer (50 mM Tris/HCl pH7.6, 250 mM NaCl, 5 mM
EDTA, 0.1% (v/v) Triton X-100) supplemented with the
protease inhibitor complete (Roche Applied Science,
Mannheim, Germany). Insoluble components were pel-
leted (12000 rpm, 4°C, 15 min) and protein concentra-
tions were determined by the Bradford protein assay (Bio-
Rad Laboratories GmbH, Munich, Germany). Samples
were dotted onto a nitrocellulose membrane (Sch-
leicher&Schuell, Dassel, Germany). Dot blots were
probed with anti Smad4 – antibody (clone B-8, Santa
Cruz Biotechnology Inc), detected with alkaline phos-
phatase-conjugated secondary antibody (DAKO, Ham-
burg, Germany) and developed using BCIP/NBT (Roche
Table 1: Association of Smad4-expression and breast cancer characteristics (n = 197). In case of histological type carcinoma other than 
ductal invasive or lobular invasive were excluded from statistical analysis (resulting n = 178). Data were calculated by Spearman's rank 
correlation test.
Smad4 negative Smad4 positive rhos (95% confidence 
interval)
p
tumor size
T1 15 37 0.007 0.924
T2 15 84 (-0.133, 0.147)
T3 81 2
T4 62 0
nodal status
N0 18 64 -0.002 0.977
N1 23 77 (-0.142, 0.138)
N2 28
N3 14
metastases
M0 43 147 0.037 0.605
M1 1 6 (-0.102, 0.176)
histologic grade
G1 3 4 0.004 0.956
G2 25 97 (-0.136, 0.144)
G3 16 52
histological type
ductal carcinoma 29 127 -0.144 0.055
lobular carcinoma 8 14 (-0.285, 0.003)
(others) 7 12
WHO stage
I1 1 2 4 0 . 2 2 0 . 7 6 0
II 19 89 (-0.118, 0.161)
III 13 34
IV 1 6
ER
positive 28 94 0.019 0.793
negative 16 59 (-0.122, 0.157)
PR
positive 30 90 0.08 0.265
negative 14 63 (-0.061, 0.218)
TβRI
positive 27 129 0.235 0.001
negative 17 24 (0.098, 0.532)
TβRII 0.023
positive 25 114 0.162
negative 19 39 (0.022, 0.295)BMC Cancer 2006, 6:25 http://www.biomedcentral.com/1471-2407/6/25
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Detection of Smad4 in breast cancer cell lines, tumor tissues and surrounding normal breast epithelia using the monoclonal  antibody clone B-8 Figure 1
Detection of Smad4 in breast cancer cell lines, tumor tissues and surrounding normal breast epithelia using 
the monoclonal antibody clone B-8. (a) Detection of Smad4 in dilution series of total protein lysates of breast cancer tis-
sue and MCF7 cells by dot blot. (b) Detection of Smad4 expression in Smad4 negative MDA468 cells, non malignant, immortal 
MCF10A cells, and Ras-transformed, increasingly malignant MCF10A derived cell lines by Western blot. Immunohistochemical 
detection of Smad4 in breast cancer cell lines (c: MDA 468; d: MCF10CA1a), breast carcinoma (e-h, j,k), and surrounding nor-
mal breast epithelia (i). Staining intensity varied between specimens: none (c,e), weak (f), moderate (d,g), and strong (h). Cyto-
plasm as well as nuclei stained positive (d,f-h). Within the same specimen tumor cells stained less than surrounding normal 
epithelia. (i) Lobular (closed arrowhead) and ductal (open arrowhead) breast epithelium, (j) lobular breast epithelium (closed 
arrowhead) and lobular breast carcinoma (open arrowhead), (k) ductal breast epithelium (closed arrowhead), ductal breast 
carcinoma (open arrowhead) and ductal breast carcinoma in situ (arrow).
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Applied Science) solution (100 mM Tris/HCl pH9.5, 100
mM NaCl, 50 mM MgCl2, NBT 100 µl/100 ml, BCIP 75
µl/100 ml)
Statistical analysis
IRS values calculated for breast cancer and adjacent nor-
mal breast epithelia originating from the same slide were
compared by paired two-sample sign test. Cross tabula-
tions were analyzed by Spearman's rank correlation test.
Survival time analysis was done by the Kaplan-Meier esti-
mator [24] and the log-rank test [25]. p-values < 0.05 were
considered to be significant. No p-value was adjusted for
possible multiple testing. Analysis was performed using
SPSS version 10.0 for both, patient with "unknown cause
of death" classified as "death due to cancer" and as "death
not due to cancer", and similar results were obtained for
both analyses; results shown in this work were obtained
by the analyses classifying "unknown cause of death" as
"death not due to cancer".
Results
Patients
The median age of the study population was 56 years
(range: 26 years to 86 years). The median follow-up was
68 months (range 2 months to 184 months). 96 % of
patients had stage I, II or III breast cancer (stage I: 17.7 %,
stage II: 54.8%, stage III: 23.9 %, stage IV: 3.6 %). After
surgery was performed 103 patients received radiother-
apy, and 158 patients underwent chemotherapy. Further
characteristics (TNM staging, histological grade, histolog-
ical type, steroid receptor status, and TGF-β-receptor sta-
tus) are listed in Table 1. Survival time analysis
demonstrated that well known prognostic factors signifi-
cantly influenced 5-year survival time in our collective
(a) Expression of Smad4 as indicated by IRS in lobular and ductal breast carcinoma compared to surrounding normal lobular  and ductal breast epithelia of the same specimen (n = 50) Figure 2
(a) Expression of Smad4 as indicated by IRS in lobular and ductal breast carcinoma compared to surrounding normal lobular 
and ductal breast epithelia of the same specimen (n = 50). Median, 1. and 3. quartile, highest and lowest IRS-value are shown (p 
< 0.001, sign-test). (b) Correlation according to Spearman between expression of Smad 4 and expression of TβRI (upper 
panel) and TβRII (lower panel), respectively (n = 197). For each IRS value of Smad4 the median IRS of TβRI and TβRII is 
denoted by a square. For exploratory reasons a regression line is fitted.
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(tumor size, T, p = 0.0002; nodal status, N, p = 0.0002;
metastases, M, p < 0.001; WHO stage, p < 0.001).
Immunostaining of Smad4 can be used to determine 
Smad4 expression
Western blotting of lysates of human breast cancer cell
lines revealed that the monoclonal antibody to Smad4
correctly identified a protein of 63kDa, just slightly
smaller than ectopically expressed flag-tagged human
Smad4 used as a positive control (data not shown). A dot
blot set up with serial dilutions of total protein extracts
from tumor tissues as well as MCF-7 cells showed decreas-
ing signal intensities with decreasing Smad4-concentra-
tions (Fig. 1a). Western Blot analysis of breast cancer cells
of increasing malignancy (MCF10A, MCF10At1k.cl2,
MCF10CA1h, MCF10CA1a [26-28]; Fig. 1b) showed that
Smad4 expression decreased with increasing malignancy
of the tumor cell line (Fig. 1b). MDA-MB-468 cells, which
do not express Smad4 due to a deletion of the Smad4 gene
[29], served as negative control (Fig. 1b). Consistently,
immunostaining was positive in MCF10CA1a cells
whereas MDA-MB-468 cells remained Smad4 negative
(Fig. 1c,d). These results demonstrated that anti-Smad4
clone B-8 could be used to determine Smad4 expression
in breast cancer tissues by immunohistochemistry, as
already described by other authors [14,15].
Smad4 expression in tumor tissues and surrounding normal 
tissues
To investigate whether this same inverse relationship of
Smad4 staining and degree of malignancy observed in the
MCF10A-derived series of cell lines would be seen in
human breast cancers, we performed an immunohisto-
chemical analysis of the expression of Smad4 in archival
tissues of 197 breast cancer patients. Immunohistochem-
istry revealed both cytoplasmic and nuclear staining for
Smad4 in both normal breast epithelia and breast carcino-
mas (Fig. 1e–k). There was no significant change in the
intracellular localization of Smad4 in the tumor tissues as
compared to the surrounding normal epithelium (data
not shown). The staining intensity varied greatly in both
uninvolved breast epithelia and tumor tissues from differ-
ent patients (Fig. 1e–h). Applying the IRS criteria (see
Materials and Methods), 23% of the tumor tissues were
Smad4-negative (IRS = 0), and a further 41 % stained
weakly positive (1 ≤ IRS ≤ 3). In general, Smad4 immu-
nostaining was stronger in the surrounding normal breast
epithelia than in tumor tissues. Therefore Smad4 expres-
sion of tumor tissues and the surrounding normal tissues
was compared (Fig. 1i–k). Overall Smad4-expression was
significantly lower in breast carcinoma (median IRS: 3)
than in normal breast epithelia (median IRS: 8, p < 0.001,
n = 50, sign test; Fig. 2a). This effect was robust when sub-
groups were formed (lobular carcinoma, ductal carci-
noma): Lobular breast epithelia had a median IRS of 12,
while the median IRS of lobular carcinomas was 2.5 (p =
0.031, n = 6, sign test). Ductal breast epithelia had a
median IRS of 8 whereas ductal breast carcinomas had a
median IRS of 3 (p < 0.001, n = 44, sign test). Thus these
data are consistent with the pattern observed in the series
of cell lines using Western blotting where Smad4 expres-
sion was higher in the less malignant MCF10A and
MCF10At1k.cl2 cells as compared to the xenograft form-
ing cell lines MCF10CA1h and MCF10CA1a (Fig. 1b).
Correlation of the expression of Smad4 and TGF-β-
receptors
Since Smad4 is a key component of the TGF-β-signaling
pathway, we investigated its expression compared to that
of the TGF-β-receptors. Smad4-expression correlated sig-
nificantly with the expression of TβRI (ρS = 0.366, p <
0.001, Spearman's rank correlation test; Fig. 2b, upper
panel) and TβRII (ρS = 0.286, p < 0.001, Spearman's rank
correlation test; Fig. 2b, lower panel) as well as with the
coexpression of TβRI and TβRII (ρS = 0.345, p < 0.001,
Spearman's rank correlation test, data not shown).
Correlation of Smad4-expression with prognostic 
parameters and influence of Smad4 on overall survival 
time
Further analysis of the data revealed no significant corre-
lation between Smad4-expression (negative: IRS = 0, pos-
itive: 1≤IRS≤12) and other established prognostic
parameters (tumor size, nodal status, metastases, histo-
logical grade, histological type, WHO stage, and steroid
receptors, Table 1). While not achieving significance, the
survival curve of Smad4-negative patients (5-year survival
rate: 92.4%) was slightly better than that of Smad4-posi-
tive patients (5-year survival rate: 74.5%, median follow-
up time: 68 months, p = 0.187, log-rank test; Table 2).
Stratifying the collective with regard to the WHO stage not
only showed a trend for longer survival in the group of
Smad4 negative patients compared to Smad4 positive
patients, but also revealed that this effect became most
prominent, though still not statistically significant, at
WHO stage III patients that already have positive lymph
nodes but no distant metastasis (Table 2). In our collec-
tive, the group WHO stage IV included only 7 patients, 1
of them being Smad4 negative, so that results of the statis-
tical analysis of this group were not meaningful. However,
pooling of the groups WHO stage I and II as well as WHO
stage III and IV again showed a trend toward a positive
influence of Smad4 loss on 5-year survival that was pro-
nounced in advanced tumor stages (Table 2). For further
analysis, we stratified our dataset with regard to tumor
size, nodal status (Table 2) and distant metastasis (data
not shown). Overall, loss of Smad4 expression correlated
with increased 5-year survival rates in these groups, but
again without reaching statistical significance. The most
distinct, but not statistically significant, impact of Smad4BMC Cancer 2006, 6:25 http://www.biomedcentral.com/1471-2407/6/25
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loss was seen as a trend for an increase in 5-year survival
from 59% to 91.1% in the group N1.
Because of the central role of Smad4 in TGF-β signaling
and the well-described cross-talk of TGF-β and estrogen
signaling [30-32], survival curve analysis was performed
after stratifying the collective with regard to ER, TβRI, and
TβRII (Table 2). Although no significant influence of
Smad4 expression on survival curves could be shown for
any group, nevertheless there was a trend towards higher
5-year survival rate in TβRII negative, Smad4 negative
patients (5-year survival rate: 100%, n = 19) than in TβRII
negative, Smad4 positive patients (5-year survival rate:
80%, n = 39), or TβRII positive, Smad4 negative patients
(5-year survival rate: 85%, n = 25,) and TβRII positive,
Smad4 positive patients (5-year survival rate: 72.8%, n =
114). Taken together, patients with a "double hit" in the
TGF-β pathway had the highest 5-year survival rate, fol-
lowed by patients with a "single hit", whereas those with
intact signaling showed the worst survival. There was no
survival effect for the presence or absence of TβRI, which
is much less prevalently altered in cancer than the ligand-
binding TβRII, whereas the effect of Smad4 could still be
seen in this stratification. Stratifying for ER again revealed
a trend for longer 5-year survival rate in Smad4 negative
patients than in Smad4 positive patients, as well as a trend
towards a longer 5 year survival rate in Smad4 positive, ER
positive patients (78.9%) as compared to Smad4 positive,
ER negative patients (66.5%; Table 2), consistent with the
known effect of the ER status on survival.
Discussion
We have used immunohistochemical staining to show
that Smad4 expression is markedly decreased in breast
cancer compared to surrounding normal breast epithe-
lium. Smad4 staining correlated with the expression of
TβRI and TβRII. In Smad4 negative patients of stage III
breast cancer, i.e. in patients with positive lymph nodes at
primary diagnosis, a trend for an increased 5-year survival
was observed.
Although the expression of Smad4 in breast cancer tissues
as well as in normal epithelia varied greatly between spec-
imens from individual patients, Smad4 expression was
significantly reduced in tumor tissues as compared to the
surrounding normal epithelia within the same specimen.
Overall, we found that 23% of the specimens were Smad4
negative and that a further 41% stained weakly. In con-
Table 2: Analysis of survival time of Smad4-positive and Smad4-negative patients stratified with regard to tumor stage, ER-status, 
TβRI-status, and TβRII-status. 5-year survival rates were computed by the Kaplan-Meier estimator. Survival curves were compared by 
log-rank test (n = 197).
5 year survival Total number Log rank test
Number censored p
Smad4 negative Smad4 positive Smad4 negative Smad4 positive Smad4 negative Smad4 positive
Unstratified 92.4 74.5 44 153 35 111 0.187
W H O  I1 0 0 . 0 * 8 6 . 7 1 12 41 11 9 0 . 1 3 5
WHO II 94.4 81.3 19 89 15 71 0.821
WHO III 92.3 54.7 1 3 3 491 9 0 . 1 3 7
WHO IV 0 20.8 1 6 0 2 0.661
WHO I/II 96.2 82.5 30 113 26 90 0.32
WHO III/IV 84.4 50.2 1 4 4 092 1 0 . 1 2 1
T1 1 0 0 . 0 8 3 . 7 1 53 71 42 9 0 . 2 0 9
T2 93.3 71.2 15 84 11 57 0.448
T3 87.5 63.5 8 12 5 8 0.899
T4 50.0 45.5 6 20 2 9 0.588
N0 94.1 88.1 18 64 16 52 0.425
N1 91.1 59.0 23 77 15 45 0.167
N2 50.0 52.5 2 8 1 4 0.666
N3 05 0 . 01 4 0 2 0 . 9 4 8
N1–3 84.3 57.9 26 89 16 51 0.227
ER negative 93.8 66.5 16 59 13 41 0.278
ER positive 91.7 78.9 28 94 22 70 0.474
TβRI negative 94.1 76.5 17 24 16 19 0.245
TβRI positive 92.3 74.1 27 129 19 92 0.523
TβRII negative 100.0 80 19 39 17 30 0.133
TβRII positive 85.9 72.8 25 114 18 81 0.806
* survival times could not be computed as all cases were censoredBMC Cancer 2006, 6:25 http://www.biomedcentral.com/1471-2407/6/25
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trast, a tissue microarray analysis of Smad4 expression in
456 cases of breast carcinomas by Xie et al. [33], reported
that only 2% breast cancer tissues were Smad4-negative.
This difference might be due to the different age of the
specimens, which was up to 70 years in the set used by Xie
et al. [33], and to staining methods employing different
secondary detection methods, as well as to the different
analysis of the specimens. Another recently published
paper [34] showed that Smad4 mRNA expression is
reduced in ductal carcinoma as compared to normal tis-
sues. At the protein level, we have shown that in the
MCF10-system of genetically related cell lines of differing
degrees of malignancy, Smad4 levels were higher in non-
malignant MCF10A cells than in the increasingly malig-
nant cell lines MCF10At1k.cl2, MCF10CA1h, and
MCF10CA1a, indicating that decreased Smad4 protein
expression might accompany tumor progression from
early stages on in-situ and in-vivo. The reduced expression
of Smad4 observed in this study could have resulted either
from decreased transcription rates from the Smad4 gene or
from increased degradation of the Smad4 protein. The lat-
ter appears more probable as various studies have shown
that the steady state level of Smad4 is tightly regulated by
ubiquitinylation [35,36] and sumoylation [37,38].
TGF-β inhibits cell proliferation in breast epithelial cells
and many breast cancer cell lines [21]. In our specimens,
Smad4 expression in tumor tissue was lower than in sur-
rounding epithelia, indicating impaired TGF-β signaling
and possible escape from TGF-β-dependent growth inhi-
bition. Given the central role of Smad4 in the signaling of
all TGF-β-related superfamily members, reduced or absent
Smad4-expression as described here would be expected to
alter the signaling not only of TGF-β, but also of the BMPs
and activins, which also can inhibit proliferation of breast
cancer cells [39-41]. Of these proteins, TGF-β, that addi-
tionally signals via MAPK-pathways [42] and interacts
with ER signaling [30], paradoxically also exhibits pro-
metastatic activity in later stages of cancer progression
[7,42]. Consistent with this pro-metastatic role of TGF-β
we have previously shown that loss of TβRII expression
correlated significantly with better prognosis in estrogen
receptor negative breast cancer patients [12]. In this work
we show that loss of Smad4 expression as a trend corre-
lates with increased survival times. Although not reaching
significance, this effect was found in all subgroups. Recent
data showing that growth of primary xenografted tumors
of MDA-MB-231 human breast cancer cells in mice is not
affected by the Smad4 status, whereas metastasis of these
cells to bone is Smad4-dependent, provide a basis for the
trend we have observed of increased survival times in
Smad4 negative patients[43]. This trend showing an effect
of Smad4 on survival time was most prominent in TβRII
negative patients indicating that silencing of TGF-β signal
transduction via the Smad pathway might improve
patient survival. Similarly, the trend towards higher 5-year
survival rate of Smad4 positive, ER positive patients as
compared to Smad4 positive, ER negative patients might
be due to interaction of ER and Smad3 that is known to
inhibit TGF-β signal transduction [30], again presumably
reducing the pro-metastatic effect of TGF-β.
Survival in breast cancer patients that undergo surgery of
the primary tumor greatly depends on the systemic spread
of the tumor and complications caused by metastasis. In
our collective, loss of Smad4 showed a trend towards
improved survival of patients with advanced disease
(WHO stage 3/4), and was particularly striking for WHO
stage 3, whereas the data of patients at stage 4 were weak
due to the low case number. This effect was likely due to
the benefit of loss of Smad4 in patients with positive
nodal status, as Smad4 negative patients staged N1 had a
50% increased 5-year survival rate as compared to Smad4
positive patients. Similarly, biallelic loss of TβRII expres-
sion due to microsatellite instability has previously been
reported to positively influence the prognosis particularly
of node positive patients suffering from colon cancer [44].
In our studies loss of Smad4 and TGFβRII showed a trend
for longer survival times in subgroups (N1 or ER negative,
respectively), but loss of Smad2-phosphorylation was pre-
viously correlated with a worse all-over survival in node
positive breast cancer [33]. On the other hand, in-vivo
data obtained by employing different mouse models of
breast cancer [8,21,23,45] indicate that reducing TGF-β-
signaling by impairing TβRII, TβRI kinase activity or
Smad3-phosphorylation enhances development of the
primary lesion but reduces metastasis whereas constitu-
tive activation of TβRI has opposite effects. These seem-
ingly contradictory results might be due, at least in part, to
the distinct roles of Smad2, Smad3, and Smad4 in TGF-β
signaling in the changing signaling context of cancer pro-
gression, resulting in altered target gene expression and
ultimately different biological effects. TGF-β signaling via
canonical and non-canonical pathways is complex, and
the all-over effect of TGF-β on cell behavior is context
dependent. Based on this complexity, the power of the
exploratory study presented here is limited, although the
results are consistent with the current literature. It will be
the goal of future work to further elucidate the role of
TGF-β and the proteins involved in TGF-β signal transduc-
tion in progression of breast cancer.
Conclusion
Our data show that Smad4 expression in breast cancer is
lower than in normal adjacent breast epithelial tissue and
imply that impairment of TGF-β/Smad-signaling because
of loss of TβRII or Smad4 might improve 5-year survival
by possibly slowing down metastases. Our data from
human tumors, although not achieving statistical signifi-BMC Cancer 2006, 6:25 http://www.biomedcentral.com/1471-2407/6/25
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cance, are in agreement with results obtained in vitro and
in animal models, where reduced TGF-β signaling pro-
vides a survival benefit in advanced tumor stages due to
decreased metastases.
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